Research and innovation underwrite excellence and are core activities of the liver centre at the Royal Free, which works in partnership with University College London, ranked fourth best university in the world.
Research at the Royal Free stretches from basic laboratory studies, looking to the future in the exploration of gene therapy, cell therapy, and bio-artificial livers and the development of fibrosis, to the assessment today in the clinical arena of the newest therapeutic drugs and endoscopic techniques.
Our consultants have contributed internationally at the highest level across the whole spectrum of liver disease.
Pathogenesis and markers in HPB cancers. Supported by an established Biobank with over 600 samples collected over 15 years. Research themes include HCC development and treatment, chemotherapy responses and trace elements in colorectal metastases, tumour metabolome in pancreatic cancer and apoptosis modulation in cholangiocarcinoma. Collaborative research is undertaken with UCL Oncology, other cancer groups and industry.
Complications of Cirrhosis
There are multiple projects on bleeding, infection, fluid retention, renal failure, hepatocellular cancer, coagulation in patients with cirrhosis as well as the monitoring and assessment of fibrosis.
Liver tissue engineering group (LTEG)
Major themes are organ preservation injury, cryopreservation, ischaemia-reperfusion injury and its modulation by pharmacological agents, direct and remote pre-conditioning. Extensive basic experimental work and first in man remote pre-conditioning trial in liver surgery. Bioengineering, nanotechnology and stem cell expertise focus on bio-artificial liver and technology developments in liver surgery techniques.